Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations ...

Among her must-haves are combo she takes “when I’m down bad” and a “more potent nasal decongestant” than DayQuil.

Emphysema is a chronic lung condition that affects millions of people worldwide and can make everyday activities such as ...

No link was found between Competitive Bidding Program implementation and changes in supplemental oxygen use or clinical ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) started 2024 on a strong note and performed well through the first half of the year. Regeneron's stock could soar by 50% in the next year from ...

One of them will be for itepekimab, a potential medicine for COPD in former smokers that is ... just identified what they believe are the 10 best stocks for investors to buy now… and Regeneron ...

It might even grow its sales faster since the COPD indication in the U.S. is still so fresh. Regeneron's lineup also features Libtayo, a cancer medicine whose rights it shares with its Dupixent ...